Maxwell Biosciences (Seed)
Funding Details
- Awarder
- Inbox
- Date Award
- March 10, 2022
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $10,800,000
Company Info
- Founding Year
- 2016
- Traction
- Demonstrated effectiveness against coronaviruses in preclinical studies.
- Founders
- Joshua McClure
- Company Description
- Maxwell Biosciences is developing a first-in-class, peptidomimetic drug platform that outputs low-molecular weight compounds designed to functionally mimic human peptides for the treatment of disease. Their biomimetic therapeutics have been shown to be effective against all coronaviruses tested, including SARS-CoV-2, and are well tolerated in human tissues.
- Market
- Pharmaceuticals
- Location
- Austin, Texas, USA
- Coinvestors
- DecentraNet, Harvard Business School Angels, Joseph Ventures, Keiretsu Forum, Star Lake Bioventures